HomeCompareLDRS vs JNJ

LDRS vs JNJ: Dividend Comparison 2026

LDRS yields 7.07% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LDRS wins by $11.9K in total portfolio value
10 years
LDRS
LDRS
● Live price
7.07%
Share price
$28.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.9K
Annual income
$1,108.63
Full LDRS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — LDRS vs JNJ

📍 LDRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLDRSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LDRS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LDRS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LDRS
Annual income on $10K today (after 15% tax)
$601.34/yr
After 10yr DRIP, annual income (after tax)
$942.34/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, LDRS beats the other by $238.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LDRS + JNJ for your $10,000?

LDRS: 50%JNJ: 50%
100% JNJ50/50100% LDRS
Portfolio after 10yr
$26.0K
Annual income
$968.20/yr
Blended yield
3.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

LDRS
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LDRS buys
0
JNJ buys
0
No recent congressional trades found for LDRS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLDRSJNJ
Forward yield7.07%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$31.9K$20.0K
Annual income after 10y$1,108.63$827.78
Total dividends collected$9.1K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LDRS vs JNJ ($10,000, DRIP)

YearLDRS PortfolioLDRS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,407$707.46$10,676$355.77+$731.00LDRS
2$12,960$754.24$11,407$389.39+$1.6KLDRS
3$14,668$800.85$12,198$426.53+$2.5KLDRS
4$16,542$847.10$13,056$467.62+$3.5KLDRS
5$18,593$892.81$13,987$513.12+$4.6KLDRS
6$20,832$937.85$14,998$563.56+$5.8KLDRS
7$23,273$982.06$16,098$619.52+$7.2KLDRS
8$25,927$1,025.33$17,295$681.69+$8.6KLDRS
9$28,809$1,067.55$18,599$750.82+$10.2KLDRS
10$31,935$1,108.63$20,022$827.78+$11.9KLDRS

LDRS vs JNJ: Complete Analysis 2026

LDRSStock

The investment seeks to track, before fees and expenses, the performance of the IBD® ETF Leaders Index. The fund normally invests at least 80% of its net assets (including investment borrowings) in the exchange-traded investment companies that comprise the index. It generally invests in all of the securities comprising the index in proportion to the weightings of the securities in the index. The index is a rules-based index owned and developed by Investor's Business Daily® designed to attempt to outperform the broader equity and fixed income markets. The fund is non-diversified.

Full LDRS Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this LDRS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LDRS vs SCHDLDRS vs JEPILDRS vs OLDRS vs KOLDRS vs MAINLDRS vs ABBVLDRS vs MRKLDRS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.